The rise of copyright’s blockbuster initially drove a boom for major pharmaceutical companies, however recent changes present a complicated scenario for those considering a stake. Lower-cost alternatives are eroding earnings, and persistent litigation add additional risk to the situation. While some companies could still gain from related service